| 12/22/2025 | CV | Market Commentary: Zoetis holds gains; Cytokinetics jumps; Bloom Energy higher; CoreWeave extends rebound
|
| 9/22/2025 | CV | Cytokinetics underwriters exercise full $100 million greenshoe
|
| 9/17/2025 | CV | Market Commentary: Cytokinetics, Pebblebrook, Adtran convertible notes price, expand on trading debut
|
| 9/17/2025 | CVLM | Cytokinetics aims to exchange $399.5 million 2027 notes for cash, stock
|
| 9/17/2025 | CV | Market Commentary: Morning Commentary: Cytokinetics, Pebblebrook, Adtran convertibles price, trade up
|
| 9/17/2025 | CV | New Issue: Cytokinetics sells upsized $650 million six-year convertible notes at 1.75%, up 37.5%
|
| 9/16/2025 | CV | Market Commentary: Cytokinetics to price overnight; Adtran notes eyed; Oscar Health prices, jumps on debut
|
| 9/16/2025 | CV | Cytokinetics talks $550 million six-year convertible notes to yield 1.75%-2.25%, up 32.5%-37.5%
|
| 1/11/2024 | CV | Market Commentary: Federal Realty, Evergy active; TechTarget skyrockets; Cytokinetics plummets outright
|
| 1/9/2024 | CV | Market Commentary: Federal Realty exchangeable notes in focus, expand on debut; Cytokinetics trades lower
|
| 1/8/2024 | CV | Market Commentary: Federal Realty convertibles eyed; Spirit AeroSystems under pressure; Cytokinetics active
|
| 1/5/2024 | CV | Market Commentary: OPKO Health convertibles price, drop below par on debut; PG&E active; Cytokinetics gains
|
| 1/4/2024 | CV | Market Commentary: OPKO convertible offering eyed; refinancing wave begins; Cytokinetics rally continues
|
| 7/26/2022 | CV | Market Commentary: Ormat convertible notes add to gains; Cytokinetics on the rise; Coinbase under pressure
|
| 7/20/2022 | CV | Market Commentary: Envestnet convertible notes active; Silicon jumps; equities have another good day
|
| 7/6/2022 | CV | Market Commentary: Pioneer Natural Resources convertibles in focus; Cytokinetics gains; Airbnb active
|
| 7/6/2022 | CV | Cytokinetics greenshoe ups 3.5% convertibles due 2027 to $540 million
|
| 7/6/2022 | CV | Market Commentary: Morning Commentary: Pioneer Resources convertibles in focus; Cytokinetics adds to gains
|
| 7/5/2022 | CV | Market Commentary: Cytokinetics convertibles rise; Booking notes active; JPMorgan, BofA synthetics trade
|
| 7/5/2022 | CV | Market Commentary: Morning Commentary: Cytokinetics convertibles add to gains; Booking notes active early
|
| 7/1/2022 | CV | Market Commentary: Cytokinetics convertibles price, skyrocket on debut; Etsy gains; BridgeBio hits new low
|
| 7/1/2022 | CV | Market Commentary: Morning Commentary: Cytokinetics convertibles hit the aftermarket, skyrocket on debut
|
| 7/1/2022 | CV | New Issue: Cytokinetics prices $450 million five-year convertible notes to yield 3.5%, up 30%
|
| 6/30/2022 | CV | Market Commentary: Aspen Aerogels convertibles offering pulled; Cytokinetics on tap; Upstart retests lows
|
| 6/30/2022 | CV | Market Commentary: Morning Commentary: Aspen Aerogels convertibles offering pulled; Cytokinetics on tap
|
| 6/29/2022 | CV | Cytokinetics talks $450 million five-year convertible notes to yield 3%-3.5%, up 30%-35%
|
| 6/29/2022 | CV | Market Commentary: Cytokinetics convertibles on tap; Aspen Aerogels cancels; Carnival, Royal Caribbean sink
|
| 10/8/2020 | CV | Market Commentary: Fiverr convertibles skyrocket on debut; Cytokinetics expands as stock tanks; ON active
|
| 10/8/2020 | CV | Market Commentary: Morning Commentary: Fiverr prices, skyrockets on debut; Cytokinetics active, stock tanks
|
| 7/10/2020 | CV | Market Commentary: Maxeon Solar upsizes convertibles; Palo Alto, Cytokinetics active; Health Catalyst gains
|
| 11/13/2019 | CV | Cytokinetics greenshoe ups 4% seven-year convertibles to $138 million
|
| 11/8/2019 | CV | Market Commentary: Stanley Black & Decker ‘trades well’; Cytokinetics drags outright; LivePerson adds on swap
|
| 11/8/2019 | CV | Market Commentary: Morning Commentary: Stanley Black & Decker mandatory ‘trades well’; Cytokinetics drags
|
| 11/8/2019 | CV | New Issue: Cytokinetics prices upsized $120 million seven-year convertibles at 4%, up 27.5%
|
| 11/7/2019 | CV | Market Commentary: Cytokinetics looks cheap; Stanley Black & Decker tightens talk; China convertibles rise
|
| 11/7/2019 | CV | Market Commentary: Morning Commentary: Cytokinetics, Stanley Black & Decker on tap; Arbor Realty prices
|
| 11/6/2019 | CV | Market Commentary: Arbor prices upsized $230 million deal; Cytokinetics, Sierra Oncology offerings on tap
|
| 11/6/2019 | CV | Cytokinetics to price $100 million convertible notes due 2026 to yield 3.5%-4%, up 27.5%-32.5%
|
| 11/6/2019 | CV | Cytokinetics to price $100 million convertible notes due 2026
|
| 6/20/2012 | CVPP | Cytokinetics prices $59.98 million public sale of stock and preferreds
|
| 11/28/2011 | CVHYPF | Cytokinetics files $100 million shelf for common stock, preferreds
|
| 11/10/2008 | CVHY | Cytokinetics files $100 million shelf
|
| 6/14/2005 | BTCV | Cytokenetics files $100 million shelf
|
